Systemic sclerosis & Raynaud's
Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort
Authors' conclusion
Our study confirms that ppFVC is a marker of survival in SSc-ILD, supporting its use for risk stratification to identify patients who may benefit from earlier interventions and treatment. Our study also supports the role of ATA positivity as a predictive marker for ppFVC decline in this population.
Study context
- Population
- Patients with SSc-ILD on HRCT Chest with serial pulmonary function tests, large single-centre cohortlongitudinal analysis
- Participants
- 184 patients
- Exposure
- Alive vs Died within 2 years
- Aliven = 163reference
- Outcome
- Risk factors of ppFVC decline
Methodological detailssingle-centre, longitudinal, linear mixed effect models
- Single-centre
- Longitudinal
- Linear mixed effect models
Main finding
As reported in the abstract
Risk factors for ppFVC decline
- Univariate: longer disease duration (>2.37 years), ILD extent >20% and ATA positivity significantly associated with percent predicted forced vital capacity (ppFVC) decline
- Multivariate: ATA positivity the only statistically significant variable associated with ppFVC decline
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Alive | Died within 2 years | P value |
|---|---|---|---|
| Mean decline in ppFVC by survival | −0.13% | −8.28% | P-value 0.0002 for the change in ppFVC trajectory |
Mean decline in ppFVC, overall
- Overall mean decline in ppFVC (P-value 0.029)
- −0.28%
Original publication
Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort. Rheumatology (Oxford). Published 15 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →